Targeting apoptosis pathways in pancreatic cancer

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 346-358

  Arlt, Alexander ^a   Müerköster, Susanne Sebens ^a   Schäfer, Heiner ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anti cancer therapy; Chemoresistance; Programmed cell death

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AEG 35156; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FAS LIGAND; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OBATOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; RAF PROTEIN; RAS PROTEIN; SALAZOSULFAPYRIDINE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL KILLING; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY;

EID: 84876084668     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.015     Document Type: Review

References (155)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
2. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7:163-172.
3. Schneider G., Siveke J.T., Eckel F., Schmid R.M. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005, 128:1606-1625.
4. Gudjonsson B. Pancreatic cancer: survival errors and evidence. Eur. J. Gastroenterol. Hepatol. 2009, 21:1379-1382.
5. Wray C.J., Ahmad S.A., Matthews J.B., Lowy A.M. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005, 128:1626-1641.
6. Lockhart A.C., Rothenberg M.L., Berlin J.D. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005, 128:1642-1654.
7. Loos M., Kleeff J., Friess H., Buchler M.W. Surgical treatment of pancreatic cancer. Ann. NY Acad. Sci. 2008, 1138:169-180.
8. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007, 297:267-277.
9. M.W. Saif, Adjuvant treatment of pancreatic cancer in 2009: Where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. Jop 10 (2009) 373-377.
10. Rivera F., Lopez-Tarruella S., Vega-Villegas M.E., Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat. Rev. 2009, 35:335-339.
11. Wong H.H., Lemoine N.R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:412-422.
12. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell Mol. Med. 2009, 13:1221-1227.
13. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
14. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
15. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
16. Hruban R.H., Adsay N.V., Albores-Saavedra J., Compton C., Garrett E.S., Goodman S.N., Kern S.E., Klimstra D.S., Kloppel G., Longnecker D.S., Luttges J., Offerhaus G.J. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25:579-586.
17. Luttges J., Neumann S., Jesnowski R., Borries V., Lohr M., Kloppel G. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 2003, 27:e57-e62.
18. Hamacher R., Schmid R.M., Saur D., Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer 2008, 7:64.
19. Muerkoster S.S., Werbing V., Koch D., Sipos B., Ammerpohl O., Kalthoff H., Tsao M.S., Folsch U.R., Schafer H. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases. Int. J. Cancer 2008, 123:1751-1760.
20. Muerkoster S.S., Lust J., Arlt A., Hasler R., Witt M., Sebens T., Schreiber S., Folsch U.R., Schafer H. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006, 25:3973-3981.
21. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.
22. Trauzold A., Roder C., Sipos B., Karsten K., Arlt A., Jiang P., Martin-Subero J.I., Siegmund D., Muerkoster S., Pagerols-Raluy L., Siebert R., Wajant H., Kalthoff H. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. Faseb J 2005, 19:620-622.
23. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
24. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., Logsdon C.D., Abbruzzese J.L., McConkey D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:2251-2260.
25. Trauzold A., Wermann H., Arlt A., Schutze S., Schafer H., Oestern S., Roder C., Ungefroren H., Lampe E., Heinrich M., Walczak H., Kalthoff H. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001, 20:4258-4269.
26. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Roder C., Kalthoff H., Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.
27. Kaplan-Lefko P.J., Graves J.D., Zoog S.J., Pan Y., Wall J., Branstetter D.G., Moriguchi J., Coxon A., Huard J.N., Xu R., Peach M.L., Juan G., Kaufman S., Chen Q., Bianchi A., Kordich J.J., Ma M., Foltz I.N., Gliniak B.C. Conatumumab, a fully human agonist antibody to death receptor 5 induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 2010, 9:618-631.
28. Huang S., Okumura K., Sinicrope F.A. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 2009, 15:150-159.
29. Huang S., Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008, 68:2944-2951.
30. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Bhanot U., Hasel C., Moller P., Gschwend J.E., Simmet T., Debatin K.M., Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009, 69:2425-2434.
31. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Gschwend J.E., Simmet T., Debatin K.M., Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 2008, 68:7956-7965.
32. Mori T., Doi R., Kida A., Nagai K., Kami K., Ito D., Toyoda E., Kawaguchi Y., Uemoto S. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 2007, 142:281-286.
33. LaCasse E.C., Cherton-Horvat G.G., Hewitt K.E., Jerome L.J., Morris S.J., Kandimalla E.R., Yu D., Wang H., Wang W., Zhang R., Agrawal S., Gillard J.W., Durkin J.P. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 2006, 12:5231-5241.
34. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
35. Retzer-Lidl M., Schmid R.M., Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int. J. Cancer 2007, 121:66-75.
36. Murtaza I., Saleem M., Adhami V.M., Hafeez B.B., Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009, 69:1156-1165.
37. Humphreys R.C., Poortman C., McCormick K., Carrell J., Shepard L. A novel combination of a small molecule IAP inhibitor and a TRAIL-R1 monoclonal antibody synergize to induce apoptosis in pancreatic tumor cell lines. Mol. Cancer Ther. 2009, 8:C10.
38. Borja-Cacho D., Yokoyama Y., Chugh R.K., Mujumdar N.R., Dudeja V., Clawson K.A., Dawra R.K., Saluja A.K., Vickers S.M. TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. J. Gastrointest. Surg. 2010, 14:252-260.
39. Basu A., Haldar S. Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. Int. J. Oncol. 2009, 34:281-286.
40. Zhang Z., Huang Y., Newman K., Gu J., Zhang X., Wu H., Zhao M., Xianyu Z., Liu X. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Clin. Cancer Res. 2009, 15:5154-5160.
41. Morales J.C., Ruiz-Magana M.J., Carranza D., Ortiz-Ferron G., Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett. 2010, 297:91-100.
42. Sung E.S., Kim A., Park J.S., Chung J., Kwon M.H., Kim Y.S. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010, 15:1256-1269.
43. Schuler S., Fritsche P., Diersch S., Arlt A., Schmid R.M., Saur D., Schneider G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer 2010, 9:80.
44. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 2008, 8:837-848.
45. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. cell 2008, 132:344-362.
46. Holcomb B., Yip-Schneider M., Schmidt C.M. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008, 36:225-235.
47. Sebens S., Arlt A., Schafer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008, 177:151-164.
48. Loveridge C.J., MacDonald A.D., Thoms H.C., Dunlop M.G., Stark L.A. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 2008, 27:2648-2655.
49. Perkins N.D., Gilmore T.D. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13:759-772.
50. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell. 2004, 13:853-865.
51. Schneider G., Henrich A., Greiner G., Wolf V., Lovas A., Wieczorek M., Wagner T., Reichardt S., von Werder A., Schmid R.M., Weih F., Heinzel T., Saur D., Kramer O.H. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2009, 29:2795-2806.
52. Mishra A., Bharti A.C., Varghese P., Saluja D., Das B.C. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int. J. Cancer 2006, 119:2840-2850.
53. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., Schafer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002, 62:910-916.
54. Niu J., Li Z., Peng B., Chiao P.J. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J. Biol. Chem. 2004, 279:16452-16462.
55. Muerkoster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., Sebens T., Kloppel G., Kalthoff H., Folsch U.R., Schafer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64:1331-1337.
56. Muerkoster S., Arlt A., Sipos B., Witt M., Grossmann M., Kloppel G., Kalthoff H., Folsch U.R., Schafer H. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 2005, 65:1316-1324.
57. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999, 5:119-127.
58. Zhang Y., Banerjee S., Wang Z.W., Marciniak D.J., Majumdar A.P., Sarkar F.H. Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res. 2005, 65:3877-3882.
59. Arlt A., Rosenstiel P., Kruse M.L., Grohmann F., Minkenberg J., Perkins N.D., Folsch U.R., Schreiber S., Schafer H. IEX-1 directly interferes with RelA/p65 dependent transactivation and regulation of apoptosis. Biochim. Biophys. Acta 2008, 1783:941-952.
60. Sasada T., Azuma K., Hirai T., Hashida H., Kanai M., Yanagawa T., Takabayashi A. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann. Surg. Oncol. 2008, 15:609-617.
61. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009, 69:5592-5600.
62. Greten F.R., Weber C.K., Greten T.F., Schneider G., Wagner M., Adler G., Schmid R.M. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002, 123:2052-2063.
63. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008, 269:226-242.
64. Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 2008, 14:5656-5662.
65. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
66. Arlt A., Gehrz A., Muerkoster S., Vorndamm J., Kruse M.L., Folsch U.R., Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251.
67. Muerkoster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Folsch U.R., Schafer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer 2003, 104:469-476.
68. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., Schafer H. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001, 20:859-868.
69. Shan Y.S., Lin P.W. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients. Hepatogastroenterology 2007, 54:2141-2145.
70. Greten F.R., Arkan M.C., Bollrath J., Hsu L.C., Goode J., Miething C., Goktuna S.I., Neuenhahn M., Fierer J., Paxian S., Van Rooijen N., Xu Y., O'Cain T., Jaffee B.B., Busch D.H., Duyster J., Schmid R.M., Eckmann L., Karin M. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007, 130:918-931.
71. Hamacher R., Diersch S., Scheibel M., Eckel F., Mayr M., Rad R., Bajbouj M., Schmid R.M., Saur D., Schneider G. Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer. Cytokine 2009, 46:182-186.
72. Camargo M.C., Mera R., Correa P., Peek R.M., Piazuelo M.B., Sicinschi L., Schneider B.G., Zabaleta J., Fontham E.T., Goodman K.J., Ryckman K.K. IL1B polymorphisms and gastric cancer risk. Cancer Epidemiol. Biomarkers Prev. 2007, 16:635.
73. Banerjee S., Kaseb A.O., Wang Z., Kong D., Mohammad M., Padhye S., Sarkar F.H., Mohammad R.M. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 2009, 69:5575-5583.
74. Wang Z., Desmoulin S., Banerjee S., Kong D., Li Y., Deraniyagala R.L., Abbruzzese J., Sarkar F.H. Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci. 2008, 83:293-300.
75. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
76. Hatcher H., Planalp R., Cho J., Torti F.M., Torti S.V. Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008, 65:1631-1652.
77. Chen J., Wu S.Y., Ou-Yang Z.G., Zhen Y.S. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells. Acta Pharmacol. Sin. 2008, 29:614-619.
78. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:483-493.
79. Kong R., Sun B., Jiang H., Pan S., Chen H., Wang S., Krissansen G.W., Sun X. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010, 291:90-98.
80. Cohenuram M., Saif M.W. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. Jop 2007, 8:4-15.
81. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
82. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
83. Mitsudomi T., Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. Febs J. 2010, 277:301-308.
84. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., Tamai S., Matsubara O., Hatsuse K., Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29:e1-e8.
85. Kullmann F., Hollerbach S., Dollinger M.M., Harder J., Fuchs M., Messmann H., Trojan J., Gabele E., Hinke A., Hollerbach C., Endlicher E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer 2009, 100:1032-1036.
86. Philip P.A. Improving treatment of pancreatic cancer. Lancet Oncol. 2008, 9:7-8.
87. El-Rayes B.F., Ali S., Ali I.F., Philip P.A., Abbruzzese J., Sarkar F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006, 66:10553-10559.
88. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 2007, 25:1960-1966.
89. Wacker B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P.J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin. Cancer Res. 2007, 13:3913-3921.
90. Deramaudt T., Rustgi A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochim. Biophys. Acta 2005, 1756:97-101.
91. Ji B., Tsou L., Wang H., Gaiser S., Chang D.Z., Daniluk J., Bi Y., Grote T., Longnecker D.S., Logsdon C.D. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009, 137. 1072-1082.e1-6.
92. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A., Davide J.P., deSolms S.J., Dinsmore C.J., Ellis-Hutchings M.S., Kral A.M., Liu D., Lumma W.C., Machotka S.V., Rands E., Williams T.M., Graham S.L., Hartman G.D., Oliff A.I., Heimbrook D.C., Kohl N.E. Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001, 61:8758-8768.
93. Beeram M., Patnaik A., Rowinsky E.K. Regulation of c-Raf-1: therapeutic implications. Clin. Adv. Hematol. Oncol. 2003, 1:476-481.
94. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
95. Shvartsman S.Y., Hagan M.P., Yacoub A., Dent P., Wiley H.S., Lauffenburger D.A. Autocrine loops with positive feedback enable context-dependent cell signaling. Am. J. Physiol. Cell Physiol. 2002, 282:C545-C559.
96. Hamilton M., Wolfman A. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor. J. Biol. Chem. 1998, 273:28155-28162.
97. Gangarosa L.M., Sizemore N., Graves-Deal R., Oldham S.M., Der C.J., Coffey R.J. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 1997, 272:18926-18931.
98. Ishimura N., Yamasawa K., Karim Rumi M.A., Kadowaki Y., Ishihara S., Amano Y., Nio Y., Higami T., Kinoshita Y. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett. 2003, 199:169-173.
99. Campbell P.M., Groehler A.L., Lee K.M., Ouellette M.M., Khazak V., Der C.J. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007, 67:2098-2106.
100. Matsuo Y., Campbell P.M., Brekken R.A., Sung B., Ouellette M.M., Fleming J.B., Aggarwal B.B., Der C.J., Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol. Cancer Res. 2009, 7:799-808.
101. Giehl K., Skripczynski B., Mansard A., Menke A., Gierschik P. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000, 19:2930-2942.
102. Sui X., Shin S., Zhang R., Firozi P.F., Yang L., Abbruzzese J.L., Reddy S.A. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene 2009, 28:709-720.
103. Chambard J.C., Lefloch R., Pouyssegur J., Lenormand P. ERK implication in cell cycle regulation. Biochim. Biophys. Acta 2007, 1773:1299-1310.
104. Shaul Y.D., Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 2007, 1773:1213-1226.
105. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?. Cell Cycle 2009, 8:1168-1175.
106. Siu L.L., Awada A., Takimoto C.H., Piccart M., Schwartz B., Giannaris T., Lathia C., Petrenciuc O., Moore M.J. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 2006, 12:144-151.
107. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
108. Lim K.H., O'Hayer K., Adam S.J., Kendall S.D., Campbell P.M., Der C.J., Counter C.M. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 2006, 16:2385-2394.
109. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., Dohner K., Bullinger L., Sandy P., Boehm J.S., Root D.E., Jacks T., Hahn W.C., Gilliland D.G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
110. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., Frohling S., Chan E.M., Sos M.L., Michel K., Mermel C., Silver S.J., Weir B.A., Reiling J.H., Sheng Q., Gupta P.B., Wadlow R.C., Le H., Hoersch S., Wittner B.S., Ramaswamy S., Livingston D.M., Sabatini D.M., Meyerson M., Thomas R.K., Lander E.S., Mesirov J.P., Root D.E., Gilliland D.G., Jacks T., Hahn W.C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
111. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
112. Bleeker F.E., Felicioni L., Buttitta F., Lamba S., Cardone L., Rodolfo M., Scarpa A., Leenstra S., Frattini M., Barbareschi M., Grammastro M.D., Sciarrotta M.G., Zanon C., Marchetti A., Bardelli A. AKT1(E17K) in human solid tumours. Oncogene 2008, 27:5648-5650.
113. Schild C., Wirth M., Reichert M., Schmid R.M., Saur D., Schneider G. PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol. Carcinog. 2009, 48:1149-1158.
114. Lee S.H., Ryu J.K., Lee K.Y., Woo S.M., Park J.K., Yoo J.W., Kim Y.T., Yoon Y.B. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008, 259:39-49.
115. Shah S.A., Potter M.W., Hedeshian M.H., Kim R.D., Chari R.S., Callery M.P. PI-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J. Gastrointest. Surg. 2001, 5:603-612.
116. Biliran H., Banerjee S., Thakur A., Sarkar F.H., Bollig A., Ahmed F., Wu J., Sun Y., Liao J.D. C-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin. Cancer Res. 2007, 13:2811-2821.
117. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., Reddy S.A. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23:8571-8580.
118. Xu X., Ehdaie B., Ohara N., Yoshino T., Deng C.X. Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 2010, 29:674-686.
119. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., Ellwart J.W., Mustafa M., Bartenstein P., D'Haese J.G., Schoenberg M.H., Berger F., Jauch K.W., Hidalgo M., Heeschen C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
120. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
121. Brunner T.B., Geiger M., Grabenbauer G.G., Lang-Welzenbach M., Mantoni T.S., Cavallaro A., Sauer R., Hohenberger W., McKenna W.G. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 2008, 26:2699-2706.
122. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69:6539-6545.
123. Chang Q., Chen E., Hedley D.W. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol. Ther. 2009, 8:1893-1901.
124. Cao P., Maira S.M., Garcia-Echeverria C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br. J. Cancer 2009, 100:1267-1276.
125. Ito D., Fujimoto K., Mori T., Kami K., Koizumi M., Toyoda E., Kawaguchi Y., Doi R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 2006, 118:2337-2343.
126. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., Enzinger P.C., Allen B., Clark J.W., Ryan D.P., Fuchs C.S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:193-198.
127. Sessa C., Tosi D., Vigano L., Albanell J., Hess D., Maur M., Cresta S., Locatelli A., Angst R., Rojo F., Coceani N., Rivera V.M., Berk L., Haluska F., Gianni L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 2009.
128. Walker K., Padhiar M. AACR-NCI-EORTC 21st International Symposium, Molecular targets and cancer therapeutics, Part 2. IDrugs 2010, 13:10-12.
129. S.K. Pal, K. Reckamp, H. Yu, R.A. Figlin, Akt inhibitors in clinical development for the treatment of cancer, Expert Opin. Investig. Drugs, September 16, 2010 (Epub ahead of print).
130. Schneider G., Kramer O.H., Fritsche P., Schuler S., Schmid R.M., Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J. Cell Mol. Med. 2010, 14:1255-1263.
131. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
132. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280:192-200.
133. Munster P.N., Marchion D., Thomas S., Egorin M., Minton S., Springett G., Lee J.H., Simon G., Chiappori A., Sullivan D., Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101:1044-1050.
134. Richon V.M., Garcia-Vargas J., Hardwick J.S. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009, 280:201-210.
135. Siegel D., Hussein M., Belani C., Robert F., Galanis E., Richon V.M., Garcia-Vargas J., Sanz-Rodriguez C., Rizvi S. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2009, 2:31.
136. Lehmann A., Denkert C., Budczies J., Buckendahl A.C., Darb-Esfahani S., Noske A., Muller B.M., Bahra M., Neuhaus P., Dietel M., Kristiansen G., Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395.
137. Kozikowski A.P., Chen Y., Gaysin A.M., Savoy D.N., Billadeau D.D., Kim K.H. Chemistry biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 2008, 3:487-501.
138. Zilberman Y., Ballestrem C., Carramusa L., Mazitschek R., Khochbin S., Bershadsky A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J. Cell Sci. 2009, 122:3531-3541.
139. Fritsche P., Seidler B., Schuler S., Schnieke A., Gottlicher M., Schmid R.M., Saur D., Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58:1399-1409.
140. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat 2008, 11:164-179.
141. Lenz H.J. Clinical update Proteasome inhibitors in solid tumors. Cancer Treat. Rev. 2003, 29(1):41-48.
142. Nawrocki S.T., Bruns C.J., Harbison M.T., Bold R.J., Gotsch B.S., Abbruzzese J.L., Elliott P., Adams J., McConkey D.J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2002, 1:1243-1253.
143. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J., Adams J., Callery M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001, 82:110-122.
144. Alberts S.R., Foster N.R., Morton R.F., Kugler J., Schaefer P., Wiesenfeld M., Fitch T.R., Steen P., Kim G.P., Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. 2005, 16:1654-1661.
145. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
146. Rachagani S., Kumar S., Batra S.K. MicroRNA in pancreatic cancer: Pathological diagnostic and therapeutic implications. Cancer Lett. 2010, 292:8-16.
147. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
148. Weiss F.U., Marques I.J., Woltering J.M., Vlecken D.H., Aghdassi A., Partecke L.I., Heidecke C.D., Lerch M.M., Bagowski C.P. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 2009, 137:2136-2145.e1-7.
149. Torrisani J., Bournet B., du Rieu M.C., Bouisson M., Souque A., Escourrou J., Buscail L., Cordelier P. Let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum. Gene Ther. 2009, 20:831-844.
150. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
151. Svoboda M., Izakovicova Holla L., Sefr R., Vrtkova I., Kocakova I., Tichy B., Dvorak J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int. J. Oncol. 2008, 33:541-547.
152. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
153. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance. a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
154. Morganti A.G., Massaccesi M., La Torre G., Caravatta L., Piscopo A., Tambaro R., Sofo L., Sallustio G., Ingrosso M., Macchia G., Deodato F., Picardi V., Ippolito E., Cellini N., Valentini V. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann. Surg. Oncol. 2010, 17:194-205.
155. Tisdale M.J. Mechanisms of cancer cachexia. Physiol. Rev. 2009, 89:381-410.